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I. Abstract 
Trypanosoma brucei is a flagellated protozoan parasite responsible for African 
Trypanosomiasis. T. brucei is a deadly immune-evasive parasite which circulates the 
bloodstream of mammalian hosts and requires the Tsetse fly as a transmission vector. 
The parasite is capable of antigenic variation which allows it to change its glycoprotein 
coat in order to escape immune detection. Of great concern is the parasite’s growing 
resistance to various chemotherapeutic treatments which may allow for reemergence. 
Protein-arginine methyltransferases (PRMTs) are a group of proteins responsible for 
transferring methyl groups to arginine residues within proteins. Protein methylation 
causes epigenetic modification of histones or changes in protein-protein interactions 
which, in turn, leads to the regulation of a variety of biological functions including, but 
not limited to: transcriptional/translational activation or repression, signal transduction, 
protein localization, and cell differentiation. Several PRMTs have been discovered in 
T. brucei including TbPRMT1, TbPRMT3, TbPRMT5, TbPRMT6 and TbPRMT7. 
TbLpn, a lipin family protein, was discovered based on its protein interactions with 
PRMTs. Lipins act as Mg2+-dependent phosphatidate phosphatases (PAPs) which 
catalyze the dephosphorylation of phosphatidic acid (PA) to diacylglycerol (DAG). 
DAG is a powerful cell signaling molecule which can then be channeled into the 
synthesis of triacylglycerol (TAG) as well as the phospholipids phosphatidylcholine 
(PC) and phosphotidlyethanolamine (PE) via the Kennedy pathway. PE and PC are 
both core constituents of the protozoan cell membrane, and PE in particular is necessary 
for synthesis of the glycosylphosphatidylinositol (GPI) anchor. Importantly, T. brucei 
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synthesizes its phospholipids de novo, ensuring that these phospholipids are produced 
by the Kennedy pathway and not by host scavenging. To observe any methylation 
interaction between TbPRMTs and TbLpn, a methylation assay was conducted using 
Adomet as a methyl source. The results show that TbPRMT1, TbPRMT5, and 
TbPRMT7 all successfully methylated TbLpn independently in vitro. TbPRMT3 and 
TbPRMT6 were incapable of methylating TbLpn in vitro. Furthermore a phosphatidic 
acid phosphatase assay was conducted to observe how effective TbLpn functions as an 
enzyme when methylated by TbPRMTs. This assay determined the enzymatic activity 
of TbLpn based on the release of organic phosphate (Pi) released during the 
dephosphorylation of PA to DAG. Results from the phosphatidic phosphatase assay 
show that the enzymatic activity of TbLpn increases greatly following methylation by 
TbPRMT5 or TbPRMT7, but not TbPRMT1, over control TbLpn.  
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II. Introduction: 
A) Trypanosoma brucei and African Sleeping Sickness 
Human African trypanosomiasis (HAT), or African sleeping sickness, is a deadly 
immune-evasive disease prevalent in sub-Saharan Africa. It is caused by protozoan 
parasites of the species Trypanosoma brucei, named after its discoverer, David Bruce 
(1). T. brucei circulates the bloodstream and tissue fluids of both human and animal 
hosts using the Tsetse fly as a vector for transmission. The species can be further 
divided into three subspecies: Trypansoma brucei gambiense (Tbg) located in the 
Western and central Africa, Trypansoma brucei rhodesiense (Tbr) located in Eastern 
Africa, and Trypanosoma brucei brucei (Tbb), a subspecies only infective to animals 
(1). The West African form of the disease is the most common form of infection 
representing approximately 98% of all cases, and causes chronic symptoms spanning 
several months or years (1). The East African form of the disease causes much more 
acute symptoms that can progress to a serious stage of infection in just several days 
following transmission (2). Approximately 70 million people are at risk of contracting 
HAT, with an estimated infection rate of 7000 people per year as of 2012 (1). Without 
treatment, the outcome of the disease is fatal. The distribution of sleeping sickness in 
Africa is related to the geographical distribution of Tsetse flies in the continent. A large 
“fly belt” spans from Southeastern Africa to Northwestern Africa (figure 1). The impact 
on agriculture is also severe when factoring in the effects of animal trypanosomiasis. 
In Africa, many farmers use domestic cattle for meat and dairy consumption as well as 
draught labor. In all, T. brucei in addition to related species T. vivax and T. congolense, 
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cause an estimated $4.75 billion in agricultural losses annually across Tsetse infested 
Africa (2).  
 
Figure 1 Distribution of HAT in the African continent 
(http://www.microbiologybook.org/lecture/trypanosomiasis.htm) 
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B) T. brucei morphology 
T. brucei are unicellular organisms characterized by a single flagellum that allows for 
motility. They range in size from 15-35µm, and feature a compact disc of mitochondrial 
DNA termed the kinetoplast (3). They have evolved a complex life cycle based around 
their vector, the Tsetse fly, allowing them to change their morphological characteristics 
depending on their environment.  
T. brucei contains a strong yet flexible microtubule corset that allows it to survive in 
the harsh environment of its host’s bloodstream (3). This corset of microtubules is very 
tight, preventing any molecular exchange along its cell body except at the flagellar 
pocket. There, endocytosis of materials can occur, such as those used to form the 
variant surface glycoprotein coat (VSG) (3).  
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Figure 2: Trypanosoma brucei 
(http://www.cdc.gov/parasites/sleepingsickness/diagnosis.html) 
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C) Tsetse fly 
Tsetse flies include a number of species in the genus Glossina. Approximately 30 
species and subspecies have been identified, about 1/3 of which are capable vectors 
for trypanosomiasis (4). Tsetse flies are very range in size from 8 to 17 mm, 
featuring a long proboscis which extends from their oral cavity and is used to draw 
blood (4). They also fold their wings completely so that one wing rests directly on 
top of the other over their abdomen (figure 3). They prefer shaded and lush habitats 
ranging from 28-30ºC, where they can breed (5).   
 
Tsetse flies are exclusively found south of the African Saharan desert; however, 
fossilized members of Glossina have been found in Arabia and even the United 
States (4). This seems to indicate that Glossina is evolutionarily very old, and may 
have helped spread trypanosomiasis over a much greater range than it currently 
does.  
 
Transmission of trypanosomiasis to a Tsetse fly can occur through human-tsetse 
contact or animal-tsetse contact. Wild animals and domestic animals therefore act 
as reservoirs that regularly acquire the disease, making it hard to eradicate (4-7). A 
Tsetse fly may then transmit T. brucei from an infected wild animal to a human. As 
a result, African populations that live in endemic areas and depend on agriculture, 
hunting, and draught labor have the highest risk of transmission (5). Within a given 
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area, the percentage of infected individuals can vary from one village to the next 
and can infect a few isolated villages or an entire region.  
 
The sterile insect technique and pesticides are the most widely used methods for 
reducing Tsetse fly numbers. The former method introduces laboratory-bred, 
radiation-sterilized, males into the Tsetse fly population (4). Introducing sterile 
males will allow them to compete with wild-type males for reproduction with 
females. This is useful because female Tsetse flies mate only once during their 
lifetime, so females inseminated with sterile sperm will not be able to conceive any 
progeny during their lifetime. The issue with this technique is cost and 
sustainability. A large of numbers of male flies need to be raised and released to 
out-compete the wild population. In addition, only isolated areas can be selected or 
else re-invasion with wild-type males may occur.  Given financial problems in 
Africa and the continent’s vast size, this method may prove to be too expensive.  
 
9 
 
 
Figure 3: The Tsetse fly vector.  
(http://www.who.int/trypanosomiasis_african/vector/en/) 
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D) Life cycle 
The lifecycle of T. brucei is complex and begins after a mammalian host is bitten by an 
infected tsetse fly. Metacyclic trypomastigotes injected into a host migrate from the 
skin tissue chancre to the lymphatic system, and subsequently to the bloodstream (17). 
T. brucei then transforms into longer and slender bloodstream-form (BF) 
trypomastigotes which move to the tissues and various organs of the host, ultimately 
infecting the CNS (18). Some trypomastigotes in the bloodstream will differentiate into 
short and stumpy cell-arrested forms that are adapted for survival in a tsetse fly host 
(19). When a tsetse fly takes a blood meal from an infected host, trypomastigotes are 
transferred from the mammalian host to the tsetse fly midgut. Short and stumpy form 
trypomastigotes then transform into procyclic-form (PF) trypomastigotes, replicate, 
and establish a midgut infection (18). Procyclic trypomastigotes then leave the midgut 
and progress a long distance past the tsetse fly proventriculus to the salivary glands 
where they attach to the epithelium. During this migration from the midgut to the 
salivary glands, procyclic trypomastigotes differentiate into both long and short 
epimastigotes (18). Short epimastigotes attach to the salivary epithelium and ultimately 
transform into metacyclic trypomastigotes which will ultimately be transferred to a new 
mammalian host once the tsetse fly takes another blood meal.   
The metacyclic trypanosome possesses variant surface glycoproteins (VSG) which 
allow it to survive in the mammalian bloodstream in addition to a morphology that 
ranges from a long and slender form to a short and stumpy form. This contrasts from 
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the procyclic trypanosome which does not express VSG and instead expresses 
procyclin in its cell coat. 
 
 
Figure 4: Life cycle of T. brucei 
(http://www.cdc.gov/parasites/sleepingsickness/biology.html) 
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E) Variant Surface Glycoproteins: 
 
Trypanosomes contain variant surface glycoproteins (VSG) which form a protective 
cell coat throughout the mammalian infectious lifecycle. They are absent in procyclic-
form trypanosomes. Furthermore, Trypanosomes can evade the host immune system 
by serial replacement of the VSG, a process known as antigenic variation (23). This 
allows for a persistent infection as the immune system is unable to fully clear the 
parasite from the bloodstream. 
 
The VSG region is approximately 15nm thick and composed of glycoproteins arranged 
as homodimers. The VSG monomers are first synthesized and cleaved by signal 
peptidases in the endoplasmic reticulum where they are then modified by N-linked 
glycosylation (24). They are anchored in the trypanosome membrane by 
glycosylphosphatidylinositol (GPI) (25). The GPI anchor is synthesized in the 
endoplasmic reticulum by a multi-step process utilizing many enzymes including GPI-
N-acetylglucosaminyltransferase, N-inositol deacetylase, inositol acyltransferase, and 
GPI inositol deacylase (26-29). After its synthesis, the GPI anchor is attached to nascent 
VSG surface proteins by GPI transamidase and is then transported to the cell surface 
(26-29). Glycosylated VSG is exported from the ER at specific exit sites (ERES) 
utilizing COPII vesicles for transport in conjunction with the golgi apparatus (30). 
Through this process, the VSG coat undergoes a very high rate of recycling involving 
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endocytosis at the flagellar pocket equal to approximately 20,000 VSG polypeptides 
per minute (31).  
 
The trypanosome VSG coat is extremely antigenic and is therefore subjected to full 
immune surveillance from the host bloodstream. The immune system can mount an 
immune response against the majority of parasites with the exception of those (~1%) 
which express distinct and unrecognizable VSG coats (24). The major factor mediating 
this immune-evasion is serial replacement of the VSG as a result of singular expression 
of VSG genes (24). VSG expression occurs at polycistronic telomere expression sites 
(ES) such that a new, singular, VSG gene is expressed in a monoallelic fashion (32). 
All other telomeric expression sites are silenced ensuring a selected VSG locus is 
uniquely transcribed. There are estimates that approximately 250 telomeres exist 
throughout the trypanosome genome (24). Many of these telomeres also exist on 
intermediate and mini chromosomes. Furthermore, gene conversion amongst VSG 
genes and pseudogenes may create VSG mosaics that enhance the VSG archive (33). 
In all, somewhere between 20-30% of the trypanosome genome is dedicated to 
archiving more than 2000 VSG genes. This ensures that a host immune system can 
never produce enough antibodies to fully eradicate the many possible VSG coat 
antigens. Due to gene conversion and inter-strain mating in the Tsetse fly salivary 
glands, the potential VSG repertoire is huge and makes it practically impossible to 
achieve herd immunity or any vaccine strategy.  
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Figure 5: Structure of variant surface glycoprotein coat anchored in GPI  
(http://legacy.earlham.edu/~harrico/Trypanosite.htm) 
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F) Discovery and Outbreaks 
Phylogenetic studies of 18S RNA suggest that African trypanosomes diverged from 
other trypanosomes approximately 300 million years ago (5). They likely began as 
intestinal parasites, and continued this existence for millions of years. The tsetse fly did 
not appear until about 35 million years ago beginning a long parasitic relationship 
between both trypanosome and Tsetse fly (2).  
 
Three major species of trypanosome exist: T. congolense, T. vivax, and T. brucei. Each 
causes African animal trypanosomiasis, also known as Nagana. In many wild animals 
this causes mild infection, whereas domestic animals such as cattle and horses develop 
often fatal infection. This is likely because in terms of evolution, cattle have only been 
in Africa for a relatively short time, perhaps 10,000 years, whereas wild animals have 
had a much longer timespan to develop resistance to trypanosomiasis (6). The term 
“Nagana” is actually derived from the Zulu language meaning “powerless” (8). This is 
because infected domestic animals suffer a variety of stunted functions including 
fertility, growth, work force, milk yields, and mortality (6). 
 
In humans, only T. brucei subspecies T.b. gambiense and T.b. rhodesiense are capable 
of causing major symptoms. This is known as Human African trypanasomiasis, or 
HAT, as mentioned previously. The fact that humans are resistant to all other African 
trypanosome species indicates that HAT is likely a recent event in human development 
(7). In fact, many species of primates are susceptible to African animal trypanosomiasis 
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indicating that the disease may have helped select for the evolution of trypanosome-
resistant hominids (7). 
 
Although most documented reports of African trypanosomiasis date back to the 19th 
and 20th century when the cause of the disease was first discovered, African 
trypanosomiasis has plagued Africa for over a millennia. Evidence of trypanosomiasis, 
human or animal, dates back to Early Egyptian times during approximately 2000-3000 
B.C (8). During this period of time the North African continent likely contained much 
more lush vegetation than it does today, suggesting that trypanosomiasis was likely 
very prevalent during the Egyptian Empire (8). Egyptians also had access to domestic 
animals during this period and likely encountered issues raising livestock. In fact, 
medical manuscripts have been discovered noting a cattle disease with symptoms very 
similar to trypanosomiasis (8).   
 
In the early modern era many reports of HAT came from ship medical officers who 
worked for companies in the African slave-trade. In 1734, the English naval surgeon 
John Aktins published the first accurate medical report on African sleeping sickness, 
describing patients as having a “sleepy distemper” (8). In 1895 David Bruce became 
the first scientist to fully document evidence of trypanosome transmission between 
Tsetse fly, cattle, and humans (9). The species T. brucei was ultimately named after 
Bruce because of this discovery.   
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In 1896 a major Sleeping sickness epidemic hit primarily Congo and Uganda, killing 
more than 300,000 people (10). Colonial powers, worried about the effects of the 
disease on the African continent, sent scientists to develop a cure. This ultimately 
resulted in the creation of suramin and melarosoprol, two potent drugs used against the 
disease and led to the use of teste fly population control methods such as bush clearing, 
pesticides, and traps (6). A second smaller epidemic occurred in 1920 as result of 
Belgian colonization and the crowding of villagers it caused, spreading from West 
Africa to Congo (6). In 1960s African nations began gaining independence from 
colonial powers resulting in widespread destabilization (10). Many nations faced 
economic crisis that disrupted health services and medical screening processes. 
Furthermore the widely used pesticide DDT was banned in 1970 due to concerns about 
its environmental effects (10). These factors ultimately promoted the most recent 1970 
epidemic that mainly affected Angola, Congo, Southern Sudan, and Uganda (6). The 
situation only improved when eflornithine was introduced to combat late-stage T.b 
gambiense infection (6).  
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G) Diagnosis and symptoms: 
 
The initial symptoms and stages for trypanosomiasis are distinctly visible and require 
immediate medical attention. The disease is 100% fatal if untreated. Following a bite 
from an infected Tsetse fly, parasites are injected into the host tissue forming a very 
obvious chancre that takes about 5 days to form (11). Eventually the parasites will 
progress to the bloodstream and lymph nodes causing inflammation and fever. Fever is 
a good identifier of HAT since T. brucei has the unique ability to rearrange the 
glycoproteins in its cell coat, thus changing its antigenicity. This allows T. brucei to 
periodically evade the immune system, causing recurrent waves of illness and fever. 
The degree of illness and fever reflect the concentration of trypanosomes in the blood.  
 
T. b. rhodesiense parasites can easily be detected in the chancre tissue, blood, or lymph 
via microscopy. Unfortunately, because of the complexity and unavailability of 
medical tests, combined with the rapid onset of T.b. rhodeseiense, by the time most 
cases present symptoms they have already progressed from the benign easily treatable 
stage of infection to later stages of infection (10). Without treatment, death will occur 
in 1 to 4 years due to encephalitis (11).  
 
T. b. gambiense infection can be difficult to diagnose because it does not proliferate as 
quickly as T.b. rhodesiense. A person can be infected for months or even years without 
major signs or symptoms of the disease, and by the time of detection it may have 
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already progressed to a difficult to treat stage (11). Diagnosis is usually via microscopic 
examination of lymph node aspirate. Concentration techniques are frequently needed 
to detect the parasite (11).  
Eventually late-stage trypanosomes will cross the blood-brain barrier by a mechanism 
not fully understood and invade the central nervous system. This occurs just weeks 
after infection with T.b. rhodesiense and months after infection with T.b. gambiense 
(11). Infection of the CNS progresses to encephalitis which is associated with 
headache, fatigue, and neurological changes in the host such as concentration loss and 
lethargy. Eventually encephalitis progresses to somnolence and coma, which indeed 
gives the disease its characteristic name: sleeping sickness (11). 
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Figure 6: Stages of T. brucei infection 
(http://www.tulane.edu/) 
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H) Efforts to eliminate sleeping sickness and factors contributing to transmission  
 
There have been several attempts to prevent and control HAT transmission dating back 
to the late 1920s. Many attempts to curb HAT transmission have been environmental 
control methods targeting Tsetse flies. These methods included destruction of wild 
game to remove animal reservoirs, clearing woodlands and other lush areas where 
Tsetse flies breed, spraying pesticides such as DDT, setting fly traps, and introducing 
natural parasites of the Tsetse fly (12). The issue with several of these methods was 
that they were not only destructive to the Tsetse fly population, but the entire African 
environment as a whole. Furthermore, none of these methods successfully eradicated 
the Tsetse fly population. Areas subjected to bush-clearing and animal control methods 
were often re-invaded. Perhaps the most environmentally friendly method listed above 
is fly trapping which can be used as a deterrent to prevent flies from biting villagers. 
Fly traps are a highly effective method which utilize potent attractants and insecticides 
to lure and kill Tsetse flies in populated areas where human-fly contact occurs such as 
fields and streams.   
 
A major issue with control of T. brucei infection is the high prevalence of animal 
trypanosomiasis amongst livestock. Livestock owners often decide to graze their 
animals in Tsetse-infected areas because if they graze their animals in areas that lack 
lush vegetation where Tsetse fly breeding cannot occur, then they risk their animals 
dying of starvation. As a result, attempts to control the disease in animals are reliant on 
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drugs administered by livestock owners with little understanding of proper dosage of 
chemotherapy treatments (13).  
 
In the 1960s widespread screening and treatment was setup in western and central 
Africa to control highly prevalent T.b. gambiense outbreaks, while T.b. rhodesiense 
was mainly controlled via continued removal of animal resevoirs and Tsetse flies (12). 
Removal methods were successful, potentially promising the outright removal of 
trypanosomiasis. Issues arose due to African civil wars which disrupted screening in 
endemic areas, and prevented movement of medication. These disruptions to medical 
screenings and treatment caused a resurgence in the number of HAT cases (figure 5).  
 
Between 1995 and 2006, due to the stabilization of the African continent and increased 
medical funding, the total number of newly reported T. brucei cases was reduced by 
68% compared to previous years (12). Thanks to WHO support, screening with 
immunological and parasitological tests has increased drastically. HAT is currently in 
decline, but may as a result receive lower public priority by health institutions, favoring 
its resurgence. The WHO has warned against neglect and complacency by health 
institutions as resurgence is very much a possibility (13).  
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Figure 7: Population screening and number of reported T. brucei cases since the 
20th century. 
(http://web.stanford.edu/group/parasites/ParaSites2012) 
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I) Treatment: 
As mentioned, African trypanosomes can evade the immune systems of their 
mammalian hosts via antigenic variation. This changing of surface proteins prevents 
vaccination since there are a large array of potential surface proteins to vaccinate 
against.  
 
Since vaccination is improbable, current treatment for T. brucei relies on potentially 
dangerous chemotherapy treatment. These methods can be complex depending on the 
time of infection, and have been used for decades resulting in inevitable drug resistance 
from T. brucei. Chemotherapy can also have very undesirable side effects, especially 
in the case of late stage treatment, which can contain arsenic (13). Once 
trypanosomiasis has progressed to the late-CNS stage, it is also difficult to treat with 
these methods since these agents do not cross the blood-brain-barrier adequately (14).  
 
Early stage treatment includes pentamidine and suramin.  Pentamidine is an aromatic 
diamidine that accumulates in the mitochondrion and binds to the minor groove of 
DNA in a sequence-specific manner. They can change DNA topology and inhibit 
topoisomerases, thus interfering with kinetoplast replication (13). Suramin was 
released for commercial use in 1924. It has been shown to prevent the association of 
heteromeric G proteins, specifically impacting exchange of GDP for GTP by guanine 
nucleotide exchange factors (GEFs). This blocks downstream g-protein signaling (15). 
In mammalian cells, suramin has also been shown to inhibit topoisomerase II (14).  
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Figure 8: Suramin 
 
 
Figure 9: Pentamidine 
 
The top treatment for late-stage cases of HAT is melarsoprol, a toxic drug in use since 
1949. The failure rate is very high, and fatalities resulting from the drug’s toxicity can 
occur in as much as 10% of treated individuals (14). Melarsoprol inhibits glycolytic 
enzymes and phosphogluconate dehydrogenase and forms a stable complex with 
trypanothione called MelT which in turn inhibits trypanothione reductase (14). This 
results in cell death due to excessive oxidative damage. It is capable of penetrating the 
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blood brain barrier, although at only 3-4% of the concentrations found in the blood 
plasma (16). Resistance to melarosprol from T. brucei is alarmingly high, and because 
it is one of the most commonly used drugs for late-stage treatment this could indicate 
that HAT resurgence is a possibility. The alternative late-stage treatment, eflornithine, 
has limited side effects, but is costly and difficult to administer. Eflornithine 
irreversibly binds to ornithine decarboxylase (ODC), preventing its substrate ornithine 
from accessing its active site (16). Ornithine decarboxylation is necessary for cell 
growth and DNA stabilization, inhibition of this process results in cell death. The issue 
with Eflornithine is that it is unfortunately less effective against T.b rhodesiense (16). 
These two drugs are the only late-stage forms of treatment and no new treatment is 
scheduled for release. With resistance from T. brucei on the rise this could present 
issues in the future. 
 
 
 
Figure 10: Melarsoprol  
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Figure 11: Eflornithine 
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J) Resistance to treatment: 
 
As mentioned previously, drug resistance by T. brucei is a growing concern. A large 
amount of research has been conducted to investigate the causes of drug resistance. 
Trypanosomes require the uptake of essential nutrients derived from a host’s red blood 
cells, however, molecular changes in T. brucei mutants allow them to be selective at 
the channels they import cellular nutrients. Drugs that can enter the flagellar pocket 
with ease in some trypanosomes are difficult to move in resistant strains. It has been 
discovered that T. brucei possesses several distinct mechanisms that prevent drug 
import and enhance drug export. Aquaglyceroporin (AQP2) is a purine transporter that 
normally favors uptake of both melarosoprol and pentamidine (20). It also transports 
the purines adenosine and adenine which compete for uptake by AQP2. Loss of this 
purine transporter favors survival of T. brucei. This was seen in experiments where 
deletion or loss of function mutations that occur in tbAT1, the gene that codes for 
AQP2, result in drug resistance (21). Furthermore, it has been found in clinical isolates 
that AQP2 is necessary for drug sensitivity (20). 
 
In addition, tb-MRPA is a multi-drug resistance protein that enhances drug export from 
the parasite (20). Following melarosoprol uptake in wild-type cells, Melarsen oxide 
forms a complex with trypanothione thereby inhibiting it (14). Normally this complex 
termed Mel-T, results in cell death as previously mentioned. The MRPA transporter, 
however, removes Mel-T from the cell, preventing cell death. 
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Figure 12: T. brucei drug resistance via loss of purine transporter P2 and drug 
export by MRPA 
(http://www.sciencedirect.com/science/article/pii/S1471492213000020) 
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K) Protein Arginine Methyltransferases  
 
Arginine methylation is a post-translational modification resulting in the addition of 
methyl groups to the N-terminus of protein arginine residues. Methylarginine residues 
are commonly found in RNA binding proteins such as RGG/RG motifs, thereby 
influencing a wide range of physiological processes (34, 35). Protein methylation 
causes epigenetic modification of histones or changes in protein-protein interactions 
which, in turn, leads to the regulation of a variety of biological functions including, but 
not limited to: transcriptional/translational activation or repression, signal transduction, 
protein localization, and cell differentiation (35 36, 37, 38). There are nine known 
PRMTs in higher eukaryotes (PRMT1-9) and these are classified as type I, II, or III 
methyltransferases depending on the terminal arginine modification produced by each 
type of enzyme. Type IV methyltransferases have been discovered, but so far only in 
yeast (39).  
 
The first step of arginine methylation involves the transfer of AdoMet to the terminal 
nitrogen of arginine yielding omega-NG-monomethylarginine (MMA). Type III 
PRMTs will only catalyze this reaction whereas type I and II PRMTs will undergo a 
second methyl transfer reaction. In type I PRMTs this second methyl transfer reaction 
occurs on the previously methylated terminal nitrogen, yielding omega NG-NG-
asymmetric dimethylarginine (ADMA). Type II PRMTs differ in that they transfer a 
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second methyl group to an adjacent terminal nitrogen, yielding ω-NG, NG-symmetric 
dimethylarginine (SDMA) (36, 40). 
 
In T. brucei, there are at least five PRMTs that have been characterized so far. 
TbPRMT1, characterized by type-1 activity, is the predominant PRMT attributed to the 
largest production of trypanosome ADMA (41). Similar to mammalian PRMT1, 
knockdown of TbPRMT1 results in a large decrease in global ADMA in vivo as well 
as adverse cell morphology and division. Also of important note is TbPRMT6, another 
type I PRMT, which has small substrate range and was shown by RNAi in both PF and 
BF cells to be essential for cell division and growth (44). TbPRMT5 has so far been 
identified as the only PRMT with type II activity in T. brucei (42, 43). TbPRMT3 is 
another type I PRMT homologous to mammalian PRMT3 which lacks catalytic 
residues present in most type 1 PRMTs. It has been seen to associate with TbPRMT7, 
a type III PRMT, characterized by high substrate catalyzation (45). It is expected that 
TbPRMTs play a large role in trypanosome gene regulation. This is because in T. brucei 
gene regulation is largely controlled at the post-transcriptional level, and thereby 
utilizes a large amount of RNA binding proteins such as PRMTs (46).  
  
A relatively new discovery indicates there may be interactions between PRMTs, 
resulting in both competitive and synergistic methylation depending on the PRMTs 
involved. For instance, knockout of mammalian PRMT1 leads to a large decrease in 
ADMA levels as expected, but surprisingly also leads to a large increase in MMA and 
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SDMA (47). This suggests that PRMTs will undergo substrate scavenging following 
the loss of a competitor PRMT. Similarly, in T. brucei, it was found that knockdown 
of TbPRMT1 resulted in a large decrease in ADMA formation, as well as a 
correspondingly large increase in MMA formed by TbPRMT7 type III catalysation 
(48). Interestingly, knockdown of TbPRMT7 does not alter expression of TbPRMT1, 
TbPRMT3, or TbPRMT6. This may indicate T. brucei cells do not compensate for loss 
of TbPRMT7, and also further suggests that some PRMTs have greater or lesser 
importance than others (48).  
 
Unlike the previously mentioned competitive nature of some categorized PRMTs, 
TbPRMT1 and TbPRMT3 protein levels display interdependence in vivo. Knockdown 
of either TbPRMT1 or TbPRMT3 results in the depletion of the other protein, likely by 
degradation (48). This information implies that the nature of PRMTs is not fully 
understood and the mechanisms for methylation may be highly complex.  
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Figure 13: Action of Type-1 and Type-II protein arginine methyltransferases 
(http://ec.asm.org/content/10/8/1013/F1.expansion.html) 
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L) TbLpn and phospholipids  
 
The lipin protein family has been described in many organisms including mammals, 
yeast, plants, and protozoa. Lipins act as Mg2+-dependent phosphatidate phosphatases 
(PAPs) which catalyze the dephosphorylation of phosphatidic acid (PA) to 
diacylglycerol (DAG). DAG is a powerful cell signaling molecule which can then be 
channeled into the synthesis of triacylglycerol (TAG) as well as the phospholipids 
phosphatidylcholine (PC) and phosphotidlyethanolamine (PE). TAG functions as an 
energy storage molecule and the main constituent of body fat in mammals. The 
founding member of the lipin family, lipin-1, was first discovered as a candidate gene 
for mammalian lipodystrophy as seen in lipin-deficient mice. This was characterized 
by loss of body fat, fatty liver, insulin resistance, and neural degeneration due to loss 
of myelin. Furthermore, mice overexpressing transgenic lipin-1 on a high-fat diet 
induce 2-4 times more rapid weight gain than non-transgenic mice despite equivalent 
food intake (51). Lipin proteins have been shown to be dependent on Mg2+ for 
enzymatic activity to occur. Lipin proteins containing missing or truncated magnesium 
binding sites are functionally inactive (51).  
 
A lipin homologue termed TbLpn has been discovered in T. brucei. It has been shown 
to interact with a number of TbPRMTs and undergo arginine methylation in vivo (57). 
TbLpn has a molecular weight of approximately 105kDa containing characteristic lipin 
N-LIP and C-LIP domains and a DxDxT motif characteristic of phosphatidic 
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phosphatase activity (57). Most importantly, the regions outside of the N-LIP and C-
LIP domain have no homology to any known proteins, making it a good candidate drug 
target in mammals.  
 
It is hypothesized that TbLpn may be necessary for trypanosome cell survival, and is 
therefore a good candidate drug target. This is based on the fact that 
phosphatidylcholine and phosphatidylethanolamine represent the majority of cellular 
phospholipids in T. brucei, and PE in particular, is a precursor for GPI synthesis (50). 
The potential role of TbLpn in phospholipid synthesis is elevated since trypanosomes 
and other protozoa do not require TAG synthesis and therefore utilize lipins solely for 
phospholipid production chiefly via the Kennedy pathway (52, 53). Specifically, PC is 
formed by the CDP-choline branch of the Kennedy pathway and PE is produced by the 
CDP-ethanolamine branch of the Kennedy pathway (54). This is important because, 
despite being a parasitic organism which derives its nutrients from its host, T. brucei 
synthesizes its phospholipids de novo (49). This occurs via a type-II fatty-acid synthase 
which produces primarily C-16 acyl chains in procyclic-form T. brucei and C-14 
myristate in bloodstream-form T. brucei (55). Myristate is importantly utilized for GPI-
anchor production. It has been previously shown by RNAi that de novo synthesis of 
phosphatidylethanolamine involving CDP-activated intermediates is essential for BF 
T. brucei cell survival (56). In addition, T. brucei bloodstream stages have been found 
to endocytose host LDL which in combination with phospholipids may be used for 
membrane biosynthesis. (55, 56) 
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Disruption of the Kennedy pathway by targeting an early intermediate such as TbLpn 
is hypothesized to prevent phospholipid formation in T. brucei, thereby preventing GPI 
anchoring of variant surface glycoproteins or even preventing membrane synthesis 
altogether, resulting in cell death. 
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Figure 14: The production of PE and PC from phosphatidic acid via the 
Kennedy pathway (right side pathway).  
(http://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-
2760(11)00029-4) 
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M) Objectives 
 
The primary goal of this experiment is to determine any functional interaction between 
TbLpn and the various known TbPRMTs present in T. brucei (TbPRMT1, TbPRMT3, 
TbPRMT5, TbPRMT6, and TbPRMT7). To do this a methylation assay will be 
conducted using His~TbLpn as a substrate in the presence of each independent 
TbPRMT. We will then use western botting with anti-methylarginine (ASYM24) 
antibodies to analyze any interaction between the TbPRMTs and TbLpn. Since 
His~TbLpn has a predicted molecular weight of 105 kDa, if methylation occurred we 
expect to see a protein band at that molecular weight following development of the 
PVDF membrane used for the western hybridization.  
 
The secondary goal of this experiment is to assess changes in the enzymatic activity of 
TbLpn after it has undergone protein arginine methylation. As previously mentioned, 
protein arginine methylation causes changes in histone configuration or protein-protein 
interactions which, in turn, may lead to changes in the regulation of a variety of 
biological functions. To assess this, we will use a phosphatidic phosphatase assay to 
quantitate the ability of His~TbLpn to dephosphorylate PA to DAG. This will be done 
by measuring the byproduct of this reaction, inorganic phosphate (PI), with Malachite 
Green-Molybdate reagent. The enzymatic activity of TbPRMT-methylated His~TbLpn 
will then be compared to the enzymatic activity of control His~TbLpn.  
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Figure 15: Effect of protein arginine methylation on TbLpn PAP activity.  
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III. Materials and Methods 
A) Expression and Purification of Recombinant Proteins 
TbLpn was expressed in E. coli BL21 from the pET26-His10Smt3-TbLpn expression 
vector which results in the production of TbLpn fused to a His10 leader peptide 
(MGHHHHHHHHHHSSGHIEGRH) followed by the 98-amino-acid Saccharomyces 
cerevisiae Smt3 protein (Smt3 is the yeast ortholog of the small ubiquitin-like modifier 
(SUMO)). First, 25 ml of E coli BL21pET26-His10-TbLpn were grown overnight in 
LB medium containing 50 µg/ml kanamycin at 37℃ and at 225rpm. The following day, 
20 ml of the overnight culture was transferred to 2 liters of LB + 50 µg/ml kanamycin. 
This culture was incubated at 37℃ and at 225rpm for approximately 3 hours until the 
optical density reached 0.5-0.6. Next, isopropyl β-thiogalactopyranoside (IPTG) was 
added to 1 mM and ethanol to 2%. Cells were incubated overnight at 225rpm at 20℃. 
The following day, the cells were spun down at 4,000rpm for 10 minutes at 4℃ in an 
AccuSpin 3R centrifuge (Fisher Scientific). Cells were resuspended in 100 ml of lysis 
buffer (10 mM Tris [pH 8.6], 10 mM glycine, 300 mM NaCl, 10 mM imidazole, 10% 
glycerol, 10% ethanol, 4% Tween-20, and 3% Triton X-100) containing 0.05 mg/ml 
lysozyme, 0.01 mg/ml DNase I, 1 µl/ml protease inhibitors cocktail (Bio Basic), and 
lysed by sonication (4 X 30 sec at 50% intensity) on ice. The lysed cell suspension was 
centrifuged at 17,000 × g for 15 min at 4°C, and the supernatant was mixed with 2 ml 
of Probond Ni2+ resin (Invitrogen) for 12 h at 4°C. The mixture was poured into a 
column, and the flowthrough collected. Next, the resin was washed with 50 ml of wash 
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buffer (10 mM Tris [pH 7.0], 200 mM NaCl, 30 mM imidazole, 10% glycerol). Bound 
His-TbLpn was eluted with 10 ml of elution buffer (10 mM Tris [pH 7.0], 200 mM 
NaCl, 200 mM imidazole, 10% glycerol).  
MBP-TbPRMT1 was expressed in E. coli BL21 from the pMalC2-TbPRMT1 
expression vector which results in the production of a TbPRMT1 fused to the Maltose-
Binding Protein (MBP) at its N-terminus. First, 10 ml of cells were grown overnight in 
LB medium containing 100 µg/ml ampicillin at 37℃ and at 225rpm. The following 
day, 10 ml of the overnight culture was transferred to 500 ml of LB + 100 µg/ml 
ampicilin. This culture was incubated at 37℃ and at 225rpm for approximately 3 hours 
until the optical density reached 0.5-0.6. Next, IPTG was added to a final concentration 
of 0.3 mM, and incubated for 2 hours at 30℃. The following day, the cells were spun 
down at 4,000rpm for 10 minutes at 4℃ in an AccuSpin 3R centrifuge (Fisher 
Scientific). Cells were resuspended in 50 ml of lysis/wash buffer (20 mM Tris [pH 6.8], 
200 mM NaCl, 1 mM EDTA, 10% glycerol) containing 0.05 mg/ml lysozyme, 0.01 
mg/ml DNase I, 1 µl/ml protease inhibitors cocktail (Bio Basic), and lysed by 
sonication (4 X 30 sec at 50% intensity) on ice. The lysed cell suspension centrifuged 
at 17,000 × g for 15 min at 4°C, and the supernatant was mixed with 1 ml of amylose 
resin (New England Biolabs) for 12 h at 4°C. The mixture was poured into a column, 
and the flowthrough collected. The column was washed with 50 ml of lysis/wash 
buffer, and MBP-TbPRMT1 eluted with 10 ml of elution buffer (20 mM Tris [pH 6.8], 
200 mM NaCl, 1 mM EDTA, 10 mM maltose, and 10% glycerol. . 
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Expression of GST-TbPRMT3 and GST-TbPRMT5 was achieved from Escherichia 
coli BL21 containing pGEX-TbPRMT3 and pGEX-TbPRMT5 respectively. Ten ml of 
cells were grown overnight in LB medium containing 100 µg/ml ampicillin at 37℃ and 
at 225rpm. The following day, 10 ml of the overnight culture was transferred to 500 ml 
of LB + 100 µg/ml ampicilin. This culture was incubated at 37℃ and at 225rpm for 
approximately 3 hours until the optical density reached 0.5-0.6. Induction was 
performed with 0.3 mM IPTG for 2 h at 25 ºC. Cells were resuspended in lysis buffer 
(50 mM Tris [pH 8.0], 50 mM NaCl, and 5 mM ethylenediaminetetraacetic acid 
(EDTA)) containing 0.05 mg/ml lysozyme, 0.01 mg/ml DNase I, and protease inhibitor 
cocktail (Bio Basic), and lysed by sonication (4 X 30 sec at 50% intensity) on ice. The 
lysed cell suspension was centrifuged at 17,000 X g for 15 min at 4 ºC, and the 
supernatant was mixed with 1 ml of GST-Sepharose 4B resin (GE Healthcare) for 12 
h at 4 ºC.  The mixture was poured into a column and the column washed with 50 
volumes of phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4, and 5 mM EDTA [pH 8.0]).  GST-tagged proteins were 
eluted with 10 volumes of elution buffer (50 mM Tris [pH 8.0], and 10 mM reduced 
glutathione).  
C-terminally his-tagged TbPRMT6 and TbPRMT7 were expressed from pet21a-
TbPRMT6 and pet21a-TbPRMT7 respectively that had been transformed into Rosetta 
strain E. coli cells [EMD Millipore]. First, 10 ml of cells were grown overnight in LB 
medium containing 100 µg/ml ampicillin and 34 µg/ml chloramphenicol at 37℃ and at 
225rpm. The following day, 10 ml of the overnight culture was transferred to 500 ml 
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of LB + 100 µg/ml ampicillin and 34 µg/ml chloramphenicol. This culture was 
incubated at 37℃ and at 225rpm for approximately 3 hours until the optical density 
reached 0.5-0.6.  Expression of both recombinant proteins was induced with 0.5 mM 
IPTG and 2% ethanol for 1 h at 30 ºC. The proteins were then and purified as described 
for His-TbLpn. 
B) TbPRMT Methylation Assay 
A methylation assay was conducted to test the ability of TbPRMT1, TbPRMT3, 
TbPRMT5, TbPRMT6, and TbPRMT7 to methylate TbLpn as a substrate. The 
presence of methylated arginine residues was then assessed by Western hybridization 
using anti-methylarginine (anti-mRG) polyclonal antibodies. The ability of 
recombinant TbPRMTs to methylate recombinant TbLpn was assessed as followed. 
Purified His-TbLpn (1.5 µg) was incubated with 20 µl of purified recombinant 
TbPRMT1, TbPRMT3, TbPRMT5, TbPRMT6, or TbPRMT7 in the presence of 12.5 
µM S-Adenosyl-L-Methionine (SAM) in a final volume of 40 µl of PBS buffer at 30 
ºC. A negative control consisting of the components mentioned above, but without any 
TbPRMT, was also set up. All buffers contained protease inhibitor cocktail. Reactions 
were carried out for 2 hours or 18 hours at 30 ºC to allow for adequate methylation of 
TbLpn. After incubation the reactions were stopped with the addition of 5X SDS 
protein sample loading buffer (0.25% Bromophenol blue, 0.5 M dithiothreitol, 50% 
glycerol, 10% SDS) and heated at 100 ºC for 5 min. A summary of the samples is 
shown below (all volumes are in µl):  
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C) Gel Preparation and Electrophoresis 
Proteins were separated by polyacrylamide gel electrophoresis in denaturing conditions 
(SDS-PAGE). Separating gels containing 7.5% acrylamide were prepared by mixing 
938μl of 40% acrylamide solution, 1.25ml of 4X separating gel buffer (1.5M Tris (pH 
8.8), 0.4% SDS), 2.8ml of ddH2O, 5μl of N,N,N′,N′-Tetramethylethane-1,2-diamine 
(TEMED), and 75μl of 10% ammonium persulfate (APS). This was poured into a 
BioRad 1 mm-thick gel casting apparatus and allowed to polymerize. A 5% stacking 
COMPONENT 1 2 3 4 5 6 7 8 9 10 11 
10X Buffer* 16  
 
16 
 
16  
 
16  
 
16  
 
16  
 
16  
 
16  
 
16  16  16  
His~TbLpn* 
SAM* 
dH2O 24 4 4 4 4 4 4 4 4 4 4 
MBP-
TbPRMT1 
--- 20 20 --- --- --- --- --- --- --- --- 
GST-
TbPRMT3 
--- --- --- 20 20 --- --- --- --- --- --- 
GST-
TbPRMT5 
--- --- --- --- --- 20 20 --- --- --- --- 
His-TbPRMT6 --- --- --- --- --- --- --- 20 20 --- --- 
His-TbPRMT7 --- --- --- --- --- --- --- --- --- 20 20 
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gel was prepared with 312μl of 40% acrylamide, 670μl of 4X stacking gel buffer (0.5M 
Tris (pH 6.8), 0.4 % SDS)), 1.48 ml of ddH2O, 5μl of TEMED, and 30μl of 10% APS. 
This was poured into the casting apparatus until overflowing, the well comb was 
quickly added, and the gel was allowed to polymerize. Running buffer was prepared 
using 100ml 10x running buffer (0.25M Tris, 1.92M glycine, 1% SDS) mixed with 
900ml ddH20. The gel casting apparatus was placed into the running cassette with the 
short plate facing inside, and this was then submerged into the running tank. The gel 
cassette inner and outer wells were filled with 1X running buffer and the combs were 
removed. The samples were loaded in addition to 5μl of prestained PAGE ruler MW 
protein ladder (Thermo Scientific), and run at 150V for 1 hour. 
D) Electrophoretic Transfer 
The separated samples were then transferred to a polyvinylidene difluoride (PVDF) 
membrane. Transfer buffer was prepared by mixing 100ml of methanol with 50 ml of 
20X N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) buffer (0.2M CAPS (pH 
11.0)), and 850 ml of ddH20. Two pieces of gel filter/blotting paper and transfer 
membrane were cut to size. Following SDS-PAGE, the polyacrylamide gel was 
removed from the gel casting apparatus by carefully removing the front plate. The 
stacking gel was subsequently removed. The gel and filter/blotting paper were then 
equilibrated in 1X transfer buffer for 5 minutes in separate containers. The membrane 
was soaked in methanol for 2-3 sec, then the sandwich was prepared. To do this, the 
anode end of a blotting cassette (clear) was submerged into 1X transfer buffer. A 
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sponge was placed inside the blotting cassette followed by a piece of filter paper, then 
the membrane. The gel was carefully placed on top of the membrane, followed by 
another piece of filter paper, a sponge, and then shut. This sandwich was then placed 
into the transfer cassette. The transfer tank was then filled completely with 1X transfer 
buffer, and the transfer performed at 60V for 45 minutes.  
E) Western Hybridization 
Following western transfer, the PDVF membrane was soaked in TBS buffer (50 mM 
Tris.HCl (pH 7.4), 150 mM NaCl) for 10 min with gentle shaking. The membrane was 
then blocked in TBS buffer containing 10% nonfat dry milk for 1 hour, washed twice 
for 5 min in TBS buffer containing 0.05% Tween-20 (TBS-T), and then incubated with 
ASYM24 anti-mRG polyclonal antibodies (EMD Millipore) at a 1:1,000 dilution in 
TBS-T containing 2% nonfat dry milk overnight at 4 C.  Following three 15 minute 
washes in TBS-T, the membrane was incubated with goat anti-rabbit IgGs (1:10,000) 
coupled to horseradish peroxidase (GAR-HRP) overnight at 4 C.  The membrane was 
finally washed three times for 15 min each in TBS-T containing 2% dry milk, and the 
reactive proteins detected using enhanced chemiluminescence (GE Healthcare). 
F) Phosphatidic Acid Phosphatase Assay 
In order to characterize the catalytic activity of TbLpn when it is methylated by 
TPRMTs, a phosphatidic acid phosphatase assay was conducted. The samples tested 
include unmethylated control His~TbLpn, as well as His~TbLpn that had been 
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methylated by TbPRMT1, TbPRMT5, or TbPRMT7. These were selected because they 
were previously shown via in vitro methylation assay to successfully methylate TbLpn. 
As mentioned previously, lipins such as TbLpn catalyze the dephosphorylation of 
phosphatidic acid (PA) to diacylglycerol (DAG). Phosphate (Pi) is produced during the 
dephosphorylation process, and can be measured to quantify TbLpn activity. The 
standard reaction contained 50 mM Tris-HCl buffer (pH 7.5), 1 mM MgCl2, 0.4 mM 
1,2-dioctanoyl-sn-glycero-3-phosphate (DiC8 PA) (Avanti Polar Lipids), and either 
unmethylated or methylated his~TbLpn (0.5 µg), in a total volume of 100 µl. In order 
to rule out that the enzymatic activity observed could be attributed to proteins co-
purified with the various TbPRMTs and not to the purified his~TbLpn, control 
reactions where purified TbPRMTs were present but his~TbLpn was omitted were also 
performed. Reactions were initiated by the addition of unmethylated of methylated 
his~TbLpn, and carried out in duplicate at 30 ºC for 60 min. The reaction was 
terminated by the addition of 200 μl of Malachite Green-molybdate reagent (8.5 mM 
ammonium molybdate tetrahydrate in 5 M HCl, 1.6 mM Malachite Green oxalate in 
1.66 M perchloric acid), and the color allowed to develop at room temperature for 30 
minute. The samples were diluted with 330 µl of water, and their absorbance at 660 nm 
measured. The amount of phosphate produced was quantified from a standard curve 
using 0.5–4 nmol of potassium phosphate.  The reactions were linear with time and 
protein concentration.  The enzymatic activity was expressed as the number of pmol of 
phosphate released per minute per mg of protein. 
 
48 
 
IV. Results: 
A) TbPRMT Methylation Assay 
It has previously been shown that TbLpn contains methylated arginine residues in vivo 
(Pelletier, 2014). In addition, an in vivo interaction between TbLpn and the major T. 
brucei PRMT, TbPRMT1, was demonstrated (Pelletier, 2014). In order to determine 
whether any TbPRMT can methylate TbLpn, in vitro methylation assays were 
performed utilizing TbLpn as a substrate and the five PRMTS found in T. brucei, 
TbPRMT1, TbPRMT3, TbPRMT5, TbPRMT6, and TbPRMT7, individually. 
Methylation assays were carried out using AdoMet as the methyl donor. The presence 
of asymmetric dimethylated arginine residues was assessed following gel 
electrophoresis and western hybridization using the ASYM24 polyclonal antibodies 
(EMD Millipore). These polyclonal antibodies specifically recognize arginines that 
have been modified by the post-translational addition of asymmetrical methyl groups. 
Since His~TbLpn has a predicted molecular weight of 105 kDa, if methylation was 
successful we would expect to see a protein band at that molecular weight following 
development of the PVDF membrane used for the western hybridization.  
 
Figures 16 demonstrates that TbPRMT1 and TbPRMT5 catalyze the transfer of methyl 
residues to TbLpn. Methylation of TbLpn by TbPRMT1 seems to be a faint signal, 
however, which may signify weak methylation of TbLpn (Fig. 16, lanes 2-3). We did 
detect, however, a major methylated degradation product around 55-60 kDa, which 
suggests that TbLpn is fairly well methylated by TbPRMT1 in vitro. This faint signal 
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at 105 kDa and the major methylated degradation product at 55 kDa have been 
routinely observed. On the other hand, TbPRMT3 and TbPRMT6 could not methylate 
TbLpn as seen by the lack of bands at 105kDa (Fig. 16, lanes 4-5, and Fig. 17, lanes 1-
2). It can be argued that TbLpn is methylated in vitro by TbPRMT3 and that methylated 
TbLpn is rapidly degraded to a protein of approximately 80 kDa as seen in Figure 16. 
As this has only been observed once, we do not feel confident that this result is accurate.   
 
As shown in Figure 17, while His~TbLpn was not methylated by recombinant 
TbPRMT6 (lanes 1-2), recombinant TbPRMT7 displayed a robust activity towards 
TbLpn (lanes 3-4). As a matter of fact, TbPRMT7 showed the strongest arginine 
methyltransferase of all 5 TbPRMTs towards TbLpn. An intense methylated 
degradation product around 70 kDa was also routinely observed. As for TbPRMT6 
activity, although no methylated protein corresponding to His~TbLpn was observed at 
105 kDa, a main methylated band was seen at around 40 kDa. This major methylated 
protein observed at approximately 40 kDa when TbPRMT6 was used (Fig. 17, lanes 1-
2) is likely TbPRMT6 itself. As previously reported, TbPRMT6 and its human 
homologue possess automethylation activity (44, 58).  
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Figure 16: In vitro methylation reaction assay of TbLpn by TbPRMT1, 
TbPRMT3, and TbPRMT5. His-TbLpn was used as a substrate for in vitro 
methylation assays in the absence (lane 1) or presence of recombinant MBP-TbPRMT1 
(lanes 2–3), GST-TbPRMT3 (lanes 4-5), or GST-TbPRMT5 (lanes 6-7). The assays 
were carried out at 30 °C for 2 hours (lanes 2, 4, 6) or 18 hours (lanes 1, 3, 5, 7). The 
reactions were stopped by the addition of 5X SDS-PAGE buffer, and proteins were 
separated on a 7.5% polyacrylamide gel and transferred to PVDF. The presence of 
methylated arginine residues was as assessed by probing the membrane with ASYM24 
polyclonal antibodies (1:1,000), followed by goat anti-rabbit IgGs. Signals were 
detected using chemiluminescence. Full length His~TbLpn is indicated by arrows. 
 
 
 
      MW 
      Lane 
His-CH3-TbLpn(TbPRMT1) His-CH3-TbLpn(TbPRMT3) His-CH3-TbLpn(TbPRMT5) 
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Figure 17: In vitro methylation reaction assay of TbLpn by TbPRMT6 and 
TbPRMT7. His-TbLpn was used as a substrate for in vitro methylation assays in the 
presence of recombinant His-TbPRMT6 (lanes 1–2), His-TbPRMT7 (lanes 3-4). The 
assays were carried out at 30 °C for 2 hours (lanes 1 and 3) or 18 hours (lanes 2 and 4). 
The reactions were stopped by the addition of 5X SDS-PAGE buffer, and proteins were 
separated on a 7.5% polyacrylamide gel and transferred to PVDF. The presence of 
methylated arginine residues was as assessed by probing the membrane with ASYM24 
           1                    2                            3                      4     5   
Lane
  
MW
  
His-CH3-TbLpn(TbPRMT7) His-CH3-TbLpn(TbPRMT6) 
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polyclonal antibodies (1:1,000), followed by goat anti-rabbit IgGs. Signals were 
detected using chemiluminescence. Full length His~TbLpn is indicated by an arrow. 
In figure 17, the 2 hour reactions are shown in lanes 1 and 3. The 18 hour reactions are shown 
in lanes 2 and 4. In lanes 3 and 4 methylated protein bands indicative of TbLpn methylation 
by TbPRMT7 are seen at 105 kDa. Some protein degradation is also visible at around 55 kDa 
and 40 kDa for both proteins. In lanes 1 and 2 TbPRMT6 has no bands present at 105 kDa, 
indicating no methylation of TbLpn occurred.  
 
B) Phosphatidic acid phosphatase enzymatic activity of native TbLpn 
In order to determine and quantitate possible effects of arginine methylation on TbLpn 
enzymatic activity, a phosphatidic acid phosphatase (PAP) assay was performed using 
unmethylated and TbPRMT-methylated His-TbLpn (see material and methods). In this 
assay Malachite Green-Molybdate reagent, which binds Pi and turns dark green 
depending on the amount of Pi bound, was used to quantitate TbLpn activity. 
Unmethylated His-TbLpn as well as His-TbLpn methylated by MBP-TbPRMT1, GST-
TbPRMT5, or His-TbPRMT7 were compared. Samples containing His-TbLpn 
incubated with TbPRMT3 and TbPRMT6 were not included in this assay as they were 
previously shown not interact with TbLpn. 1, 2-dioctanoyl-sn-glycero-3-phosphate 
(DiC8PA) was used as a substrate. Following addition of Malachite Green-Molybdate 
reagent, the absorbance of the samples was recorded at 660nm. A control reaction 
containing DiC8PA but lacking recombinant TbLpn was used as a negative control. 
The OD660 obtained with this control was subtracted from all experimental values. 
Additionally, PAP assays that contain the recombinant TbPRMTs without any TbLpn 
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were also performed and their OD660 values were subtracted from the values obtained 
with the respective methylated His-TbLpn. 
 
As shown in Figure 18, unmethylated His-TbLpn displayed an enzymatic activity of 
161 nmol Pi/min/mg. This is consistent with the previously reported enzymatic activity 
of recombinant unmethylated TbLpn which was shown to be in the order of 200-225 
nmol Pi/min/mg (Pelletier et al., 2013). Methylation by TbPRMT1 had no effect on the 
enzymatic activity of TbLpn (146.7 nmol Pi/min/mg), while methylation by TbPRMT5 
resulted in a 9-fold increase in the activity (1,458 nmol Pi/min/mg). The greatest 
increase in phosphatidic acid phosphatase enzymatic activity was observed when His-
TbLpn that had been methylated by recombinant TbPRMT7 was used. This led to an 
extremely robust 147-fold increase in the enzymatic activity (23,759 mmol Pi/min/mg).   
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Figure 18: Phosphatidic Acid Phosphatase activity of TbPRMT-methylated 
TbLpn vs unmethylated TbLpn. The enzymatic activity was measured by the release 
of phosphate from 1,2-dioctanoyl-sn-glycero-3-phosphate (DiC8 PA). The substrate 
was incubated with His-TbLpn (0.5 µg) either unmethylated, or previously methylated 
with either MBP-TbPRMT1, GST-TbPRMT5, of His-TbPRMT7. The amount of 
phosphate released was measured using Malachite Green-Molybdate reagent and 
recording the absorbance at 660 nm. 
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V. Discussion 
 
Lipins such as TbLpn play a very important role in the dephosphorylation of 
phosphatidic acid to form diacylglycerol (DAG). DAG can then subsequently be 
channeled into phospholipid synthesis via the Kennedy pathway. Specifically, the 
phospholipids phosphatidylcholine (PC) and phosphatidylethanolamine (PE) are both 
products of the Kennedy Pathway. These phospholipids are not only components of the 
trypanosome cell membrane, but are also precursors for the 
glycosylphosphatidylinositol (GPI) anchor. Importantly, in T. brucei phospholipids are 
synthesized de novo, meaning they cannot scavenge them from their host and must 
synthesize them from scratch.  
 
The primary goal of this experiment was to determine any functional interaction 
between TbLpn and the various known TbPRMTs present in T. brucei (TbPRMT1, 
TbPRMT3, TbPRMT5, TbPRMT6, and TbPRMT7). As mentioned previously, protein 
arginine methyltransferases can regulate a variety of biological functions including, but 
not limited to: transcriptional/translational activation or repression, signal transduction, 
protein localization, and cell differentiation (35 36, 37, 38). PRMTs are classified as 
type I, II, or III methyltransferases depending on the terminal arginine modification 
produced by each type of enzyme. The first step of arginine methylation involves the 
transfer of AdoMet to the terminal nitrogen of arginine yielding omega-NG-
monomethylarginine (MMA). Type III PRMTs will only catalyze this reaction whereas 
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type I and II PRMTs will undergo a second methyl transfer reaction. In type I PRMTs 
this second methyl transfer reaction occurs on the previously methylated terminal 
nitrogen, yielding omega NG-NG-asymmetric dimethylarginine (ADMA). Type II 
PRMTs differ in that they transfer a second methyl group to an adjacent terminal 
nitrogen, yielding ω-NG, NG-symmetric dimethylarginine (SDMA) (36, 40).  
 
A physical interaction between TbLpn and TbPRMT1 in vivo has previously been 
demonstrated (57). In addition, our lab has shown the presence of methylated arginine 
residues on TbLpn in vivo (57). Based on the information above, we hypothesized that 
changes in the protein arginine methylation status of TbLpn by TbPRMT1, and 
possibly other TbPRMTs, may alter the phospholipid composition of the trypanosome 
cell membrane. Previous studies have shown that PRMTs are present in a wide range 
of parasitic protozoa, and may therefore pose as targets for chemotherapeutic attack 
(48). TbLpn also shows little sequence homology to other mammalian lipins, making 
it a good candidate target.  
 
In order to analyze individual interactions between the various known TbPRMTs and 
TbLpn, an in vitro methylation assay was conducted. In this assay TbPRMT1, 
TbPRMT3, TbPRMT5, TbPRMT6 and TbPRMT7 were individually incubated with 
the substrate TbLpn, and AdoMet as a methyl source (see material and methods). Each 
reaction was incubated for 2 hours or 18 hours at 30 °C. These incubation periods were 
chosen because they allowed for optimal methylation of TbLpn. A reaction that 
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proceeds too long has been shown to result in excessive proteolytic degradation despite 
the presence of protease inhibitors, whereas a reaction shorter than two hours produced 
little methylation and unclear results. Following incubation to allow for optimal 
methylation, western blotting was used to observe any methylation of TbLpn by the 
TbPRMTs. The reactions were subjected to SDS-page and western blotting using a 
PVDF membrane and ASYM24 primary antibodies. ASYM24 antibodies specifically 
recognizes proteins that contain arginines that are asymmetrically dimethylated. Prior 
to ASYM24 antibodies, anti-mRG antibodies (CH3 BioSystems) were used but yielded 
poor results. This could have been due to the fact that these antibodies had been 
purchased a long time ago.  
 
The results of the methylation assay show that TbPRMT1, TbPRMT5 and TbPRMT7 
were able to transfer methyl groups to TbLpn as seen in figures 16 and 17. Figure 16 
shows a faint band for the sample His-CH3-TbLpn(TbPRMT1) at around 105 kDa after 
both 2 hours and 18 hours of methylation. This is indicative of methylated TbLpn. 
Notably, the signal for this band is relatively weak, even after 18 hours of incubation 
with TbPRMT1. Other western hybridization attempts struggled to show any 
methylation of TbLpn by TbPRMT1 after 2 hours of incubation. This seems to suggest 
that TbPRMT1 has a relatively low enzymatic rate. We did, however, detect an intense 
methylated band at approximately 55-60 kDa which likely represents a degradation 
product which, nonetheless, is methylated. This methylated degradation product has 
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been observed routinely in other in vitro methylation assays (Pelletier et al., 
unpublished data).  
 
Furthermore, TbPRMT3 was unable to methylate TbLpn as seen by the lack of a protein 
band at 105 kDa (figure 16). Some bands are visible for the lanes containing 
TbPRMT3, however, they are present at a molecular weight of approximately 55 kDa 
and 80 kDa indicating that full length TbLpn was not successfully methylated. These 
protein bands are indicative of protein degradation and were found in all sample lanes, 
suggesting a non-specific binding by the primary antibodies. Similar to TbPRMT3, 
TbPRMT6 was also unable to methylate TbLpn after both 2 hours and 18 hours of 
incubation. This was seen by a complete lack of methylarginine bands at 105kDa 
(figure 17). As with other lanes some protein degradation was found at around 70kDa. 
In the past, TbPRMT6 has been described as having a very narrow substrate specificity 
which may explain its inability to methylate TbLpn (48). As with its human homologue, 
TbPRMT6 displays automethylation activity, which likely explains the methylated 
protein observed at 40 kDa. 
 
Unlike TbPRMT1, TbPRMT3, and TbPRMT6, the methylation of TbLpn by 
TbPRMT5 produced a moderate methylation signal. This was seen by the presence of 
a protein band at 105 kDa (figure 17). It is surprising that the ASYM24 antibodies were 
able to detect the presence of methylated arginine residues on TbLpn after incubation 
with TbPRMT5 as this enzyme is a type II PRMT (catalyzes symmetrical 
59 
 
demethylation of arginines), and that the ASYM24 have been reported to recognize 
only asymmetric dimethylarginines. TbPRMT7 produced the strongest methylation of 
TbLpn as indicated by the very intense band present at 105kDa (figure 17). PRMT7 
has previously been described as highly active with a very wide substrate range, up to 
30 times more active than TbPRMT1 (47).  
 
The secondary objective of this research was to assess changes in the enzymatic activity 
of TbLpn after it has undergone protein arginine methylation. TbLpn displays PAP 
activity by dephosphorylating phosphatidic acid (PA) to form diacylglycerol (DAG), 
creating inorganic phosphate (Pi) as a byproduct. Using a PAP assay, the absorbance 
of Malachite Green-Molybdate reagent, which binds Pi and turns dark green depending 
on the amount of Pi bound, was used to quantitate TbLpn activity. The results of this 
experiment show conclusively that the enzymatic rate of TbLpn, and hence its Pi 
release, increases following individual methylation by TbPRMT5, or TbPRMT7. The 
calculated enzymatic activity for each TbPRMT was very reflective of the intensity of 
methylation signals found in figures 16 and 17. These TbPRMTs were chosen because 
they were shown to methylate TbLpn in vitro, whereas TbPRMT3 and TbPRMT6 were 
unable to and were therefore omitted from the assay.  
 
Figure 18 shows that recombinant TbLpn exhibits modest phosphatidate phosphatase 
activity. It is important to note that, as PRMTs are absent in bacteria, any protein 
expressed in E. coli will be unmethylated. From our data, we calculated that 
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recombinant, and thus unmethylated, TbLpn has a specific activity of 161 
nmol/min/mg. This is in agreement with previously published data showing a specific 
activity for recombinant TbLpn in the order of 200–225 nmol/min/mg. Figure 18 also 
reveals that, out of the tested TbPRMTs, His-CH3-TbLpn(TbPRMT7) had the greatest 
average PAP activity of 23,759mmol Pi/min/mg, while His-CH3-TbLpn(TbPRMT5) 
had a modest level of PAP activity of 1,458mmol Pi/min/mg. Incredibly, the average 
PAP activity of His-CH3-TbLpn(TbPRMT7) was 141 times higher than the average 
PAP activity of unmethylated His-TbLpn and 16 times higher than His-CH3-
TbLpn(TbPRMT5). These findings show conclusively that TbLpn PAP activity 
increases drastically following methylation by certain TbPRMTs, and that some 
TbPRMTs are capable of greater methylation than others. Interestingly, there was 
almost no statistical change between the average PAP activity of His-CH3-
TbLpn(TbPRMT1) compared to control His-TbLpn. This indicates that TbPRMT1 has 
a relatively limited ability to induce changes in TbLpn PAP activity. Overall, these 
findings coincide with the methylation assay results which revealed TbPRMT1 to have 
a very weak interaction with TbLpn, whereas TbPRMT5 and TbPRMT7 both 
interacted very strongly with TbLpn. Of note His-CH3-TbLpn(TbPRMT7) produced 
very strong methylarginine bands (figure 17) which corresponded with its extremely 
high PAP activity. It is interesting, however, that the western results show TbPRMT1 
did at least have some limited ability to methylate TbLpn (figure 16), but was incapable 
of inducing any changes in PAP activity (figure 18). Eukaryotic PRMT1s, including 
TbPRMT1, are typically responsible for about 90% of type I PRMT activity, whereas 
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PRMT5 and PRMT7 are characterized as type II and type III methyltransferases, 
respectively (47). Contrary to this information, our results suggest, at least in vitro, that 
TbLpn does not favor type I activity and instead strongly favors formation of MMA 
and SDMA via type II and type III protein arginine methylation. As mentioned above, 
the ASYM24 antibodies have been reported to recognize only asymmetric 
dimethylarginines. We can speculate that these antibodies may not be as specific for 
ADMA as intended. On the other hand, both TbPRMT5 and TbPRMT7 might produce 
some unreported ADMA. The nature of the methylated arginine residues produced by 
TbPRMT1, TbPRMT3, and TbPRMT7 could be determined by MALDI-TOF and post-
source decay analyses, an approach that was successful for the identification of 
methylation sites in many proteins.  
 
As discussed previously, other studies have revealed there may be interactions between 
PRMTs in vivo, resulting in both competitive and synergistic methylation depending 
on the PRMTs involved. Knockout of TbPRMT1, or its mammalian homologue 
PRMT1, leads to a large decrease in ADMA levels as expected from loss of type I 
activity, but also leads to a large increase in MMA and SDMA resulting from PRMT5 
and PRMT7 upregulation (47, 48). This process is called substrate scavenging. 
Interestingly, knockdown of TbPRMT7 was shown not to alter the expression of 
TbPRMT1, TbPRMT3, or TbPRMT6 indicating T. brucei cells do not compensate for 
the loss of TbPRMT7 (48). It was shown in our experiment that TbPRMT7 is the 
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dominant TbPRMT in vitro (figure 18). Based on this, knockout of TbPRMT7 may 
extremely limit TbLpn PAP activity and furthermore may not be compensated for.  
 
On the other hand, TbPRMT1 and TbPRMT3 protein levels have been shown to display 
interdependence in vivo. Knockdown of either TbPRMT1 or TbPRMT3 results in the 
depletion of the other protein, likely by degradation (48). This may explain why the 
signal found for His-CH3-TbLpn(TbPRMT1) was so weak even after 18 hours of 
incubation and why TbPRMT3 was incapable of TbLpn methylation (figure 16). It 
would also explain why His-CH3-TbLpn(TbPRMT1) produced no change in PAP 
activity over control His-TbLpn. It has been predicted this codependence occurs 
because TbPRMT1 and TbPRMT3 together form a hetero-oligiomeric complex in vivo, 
thereby being reliant on each other for sufficient enzymatic activity to occur. Based on 
this complex, the function of TbPRMT3 may serve to boost the activity of TbPRMT1. 
Of the two proteins, TbPRMT1 displayed the highest independence, as it was 
sufficiently able to cause methylation on its own whereas TbPRMT3 seems to be 
functionally inactive without its partner (figure 16). In a future study it would be 
interesting to use an in vitro methylation assay and a PAP assay to analyze the 
methylation status of TbLpn following incubation with both TbPRMT1 and TbPRMT3 
including any possible changes in its overall PAP activity. It is possible, however, that 
the association between TbPRMT1 and TbPRMT3 may only occur in vivo. 
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To summarize the findings of these experiments it is clear that (1) TbPRMT1, 
TbPRMT5, and TbPRMT7 are all capable of methylating TbLpn and that (2) protein 
arginine methylation of TbLpn by TbPTMT5 and especially TbPRMT7 results in an 
increase in TbLpn PAP activity. Based on these findings it can be predicted that 
TbPRMTs upregulate the conversion of PA to DAG by TbLpn, and may consequently 
have a large role in T. brucei phospholipid synthesis. Principle to this theory is the fact 
that trypanosomes produce their phospholipids de novo, elevating the importance of 
protein arginine methylation. TbPRMTs and their target TbLpn may therefore serve as 
important chemotherapeutic targets based on this information. Of high note is 
TbPRMT7 which was shown to greatly enhance the PAP activity of ~His-TbLpn.  
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